Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Blood - 23 Nov 2017

Chai-Adisaksopha Chatree, Brown Jennifer R

Abstract excerpt

In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Immunoglobulin Heavy Chains
Share to Immunoglobulin Variable Region

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Remission Induction

Share to Rituximab

Share to Vidarabine

Source

Identifiers

PMID: 29025740
DOI: 10.1182/blood-2017-07-731588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.PMID 29025740Read ↗

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Semantic proximity Read ↗

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.Semantic proximity Read ↗

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read ↗

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.Semantic proximity Read ↗

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.Semantic proximity Read ↗

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.Semantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.Semantic proximity Read ↗

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.Semantic proximity Read ↗

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.Semantic proximity Read ↗

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03Semantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.